At the American Society of Hematology (ASH) 2015 Annual Meeting, held in Orlando, FL., Dr Naval Daver from the University…
Browsing: Acute Lymphoblastic Leukemia
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses recommendations for the utilization of molecular factors in treatment planning…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses ongoing clinical trials that will establish a clinical role for…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers that have been identified in prognosis and risk…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses molecular markers have greater impact on risk of recurrence than…
Dr. Robert Bristow, MD of Princess Margaret Cancer Centre discusses Genetic Testing in Prostate Cancer at ASCO GU 2016
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses using new therapies earlier in prostate cancer may returns better…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses significant off-target adverse events from novel treatments directed at molecular…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses resistance to CYP17 and AR inhibitors such as the AR-7…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses new recently discovered novel targets for CCRPC at ASCO GU…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses galeterone and alternative splicing does this agent differ from approved…
Dr. David Michael Nanus, M.D. of Weill Cornell Medicine discusses the agents currently available or in research pipelines than target…
Tam Constantine, MD from Peter MacCallum Cancer Centre & St. Vincent’s Hospital Melbourne, Melbourne, Australia, gives an overview of the…
Eileen Kaner, MSc, PhD, Hon FRCP gives an overview of a session focusing lifestyle behaviour and cancer prevention presented at…
Alan Burnett, MD from Cardiff University, Cardiff, UK discusses the new technology developments in the field of acute myeloid leukemia…
Dr Naughton communicates the clinical actionability of a Low Risk/Low Likelihood of Benefit BCI result in his practice.
What is CLL? How and where does it start? CLL experts Dr. Nicole Lamanna of Columbia University Medical Center and…
From our Ask the Expert series, CLL expert Dr. Michael Keating of MD Anderson Cancer Center answers a common CLL…
Dr. Michael Keating of MD Anderson Cancer Center answers the question: Does CLL return more aggressively after relapse than it…
Toni Choueiri, MD of Dana Farber gives us Kidney Cancer Highlights from ASCO GU 2016 Genitourinary Symposium from San Francisco
Dr. Toni Choueiri, MD of Dana Farber gives an ASCO GU 2016 Update on Clear Cell and non-Clear Cell Renal…
Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses how Avelumab is tolerable for patients according to JAVELIN…
Dr. Andrea B. Apolo, MD from the National Cancer Institute discusses the next steps and moving Checkpoint Inhibitors from metastatic…
Dr. Andrea B. Apolo, MD of the National Cancer Institute discusses Safety, clinical activity, and PD-L1 expression of avelumab (MSB0010718C),…
Dr. Nima Sharifi, MD of Cleveland Clinic comments on how investigators are now looking to use new therapies earlier within…
Dr. Nima Sharifi, MD at Cleveland Clinic gives an overview of his presentation Androgen Receptor New Ways of Targeting the…
Dr. Nima Sharifi, MD at Cleveland Clinic discusses the ALLIANCE trial and the combinations of CYP17 and AR inhibitors in…
Dr. Nima Sharifi, MD of Cleveland Clinic discusses the potential role for combinations of CYP17 inhibitors and AR inhibitors in…
Dr. Nima Sharifi, MD of Cleveland Clinic answers the question How does CYP17 inhibitors and novel androgen receptor inhibitors affect…
Nima Sharifi, MD of Cleveland Clinic discusses the new Androgen Receptor Signaling and the new targets and agents for advanced…
Dr. Petros Grivas, MD at Cleveland Clinic discusses the correlation of myeloid derived suppressor cell (MDSC) populations with clinicopathologic features…
Dr. Petros Grivas, MD at Cleveland Clinic discusses atezolizumab (MPDL3280A) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC) at…
Dr. Petros Grivas, MD at Cleveland Clinic discusses the evaluation of response to enzalutamide consecutively after disease progression on abiraterone…
Dr. Petros Grivas, MD of Cleveland Clinic discusses The association of D4, 3-keto-abi (D4A) and response to abiraterone in castration-resistant…
Dr. Walter Stadler of The University of Chicago Cancer Center @UCCancerCenter discusses Choosing predictive markers for PD-1 and PD-L1 inhibitors…
“Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, explains how Bruton’s tyrosine kinase inhibitors, like ibrutinib and…
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of venetoclax (ABT-199) for the treatment…
Peter Hillmen, MBChB, PhD from St. James’ University Hospital, Leeds, UK, provides an overview of the Resonate-2 clinical trial of…
Martin JS Dyer, MA, DPhil, FRCP, FRCPath from the University of Leicester, Leicester, UK, provides an overview of a Phase…
Jacqueline Barrientos, MD, discusses the drug acalabrutinib (ACP-196), a second generation Bruton’s tirosine kinase (BTK) inhibitor that demonstrates reduced off-target…
Jacqueline Barrientos, MD, discusses a promising new study of the anti-apopotopic (Bcl-2 inhibitor) venetoclax in patients with CLL. Early data…
Jacqueline Barrientos, MD, discusses the importance of understanding treatment failure in CLL patients, and what options are available. She provides…
Jacqueline Barrientos, MD, discusses a recent follow-up study looking at CLL patient outcomes following treatment with ibrutinib, including populations that…
Dr. Walter Stadler of the University of Chicago discusses how Checkpoint inhibitors iwill mpact outcomes for advanced RCC
Dr. Walter Stadler discusses his experience with FDA approved Nivolumab and PD-1 and PD-L1 inhibitors in RCC
Patient Power founder Andrew Schorr along with patient advocate Carol Preston, on location at the 2015 American Society of Hematology…
How far have we progressed in the field of CLL research? Patient advocate Carol Preston, on location at the 2015…
Is there hope for people with Hodgkin Lymphoma? Dr. John Sweetenham, Executive Medical Director of the Huntsman Cancer Institute, says,…
Are clinical trials still valid as a means for treatment? On location at the 2015 American Society of Hematology (ASH),…
Dr. Toni Choueiri of the Dana Farber Cancer Institute discusses the subgroup analyses of METEOR, a randomized phase 3 trial…